Recon: Supreme Court seems skeptical of mifepristone challenge; Lawmakers query FDA on Neuralink inspection

• US Supreme Court appears skeptical of challenge to abortion pill access (Reuters)
• Johnson & Johnson considers deal for shockwave medical (WSJ)
• Amgen sues Colorado over its prescription drug affordability board (STAT)
• Vertex Pharmaceuticals is considering relocating its headquarters (STAT)
• Exclusive: US lawmaker seeks answers on FDA inspection of Musk's Neuralink (Reuters)
• During the pandemic, were great vaccines bad business? A company-by-company review (STAT)
• Alexion adds fourth indication for C5 inhibitor Ultomiris in rare autoimmune disorder (Endpoints)
• Regeneron's blood cancer therapy faces setback as FDA raises trial concerns (Reuters)
• Regeneron Oncology Setback Delivered By US FDA Crackdown On Accelerated Approval (Pink Sheet)
• FDA Approval of New Therapy, Duvyzat, for Duchenne Muscular Dystrophy Represents Several Meaningful Firsts (FDA Law Blog)

• How expanded methadone access helped Switzerland defuse its drug crisis (STAT)
• Brazil aims to manufacture its own cell therapies — at a fraction of the current cost (Endpoints)
• New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies (Pink Sheet)
• EU Warns Of Life-Threatening Interactions Between Paxlovid & Some Immunosuppressants (Pink Sheet)
• EU CHMP Opinions And MAA Updates (Pink Sheet)

• Merck’s next big thing is (probably) on the way (STAT)
• Viking Therapeutics to move its oral obesity drug into Phase 2 study after early success (STAT)
• Stoke unveils new data on genetic epilepsy drug — and investors are stoked (Endpoints)
• Edgewood's $20M Series A; Nanoscope to pursue FDA approval for eye gene therapy later this year (Endpoints)
• Praxis touts topline data for epilepsy drug in first of four readouts (Endpoints)
• Exclusive: Athena Countouriotis' Avenzo nabs $150M to in-license more assets (Endpoints)
• PE firm Olympus to sell up to $235 mln stake in India's Aster DM, term sheet shows (Reuters)
• How Pharma Firms Using AI Should Navigate Regulatory Submissions (Pink Sheet)
• US FDA's CDER Creates Quantitative Medicine Center Of Excellence; Job Includes AI Oversight (Pink Sheet)

• A new report questions whether digital diabetes programs are worth the cost (Endpoints)
• Phathom’s first campaign for acid blocker Voquezna is the latest to use telehealth to reach potential patients directly (Endpoints)

• Rite Aid reaches bankruptcy settlement with lenders, DOJ, McKesson (Reuters)
• Gene therapy maker bluebird to revise financials after accounting errors (Reuters)
• Incorporating Pharmacy Spending In Value-Based Payment Models Remains Challenging (Pink Sheet)